Introduction
Erythropoietic protoporphyria (EPP) is a hereditary disorder caused by a decrease in ferrochelatase activity (E.C. 4 .99.1.1). The enzyme is associated with the inner mitochondrial membrane and catalyzes the insertion of iron into protoporphyrin to form heme. 1 This defect results in a high accumulation of protoporphyrin in erythrocytes, plasma, feces and other tissues such as the liver and the skin. 1, 2 Clinically, the disease is characterized by cutaneous photosensitivity due to the photoreactive properties of protoporphyrin. Light between 360 and 450 nm initiates a chain of reactions in which protoporphyrin acts as a photochemical radical. This photosensitizing property induces an acute inflamation of the skin, characterized by burning pain, oedema and often purpura. 3 Occasionally, a mild microcytic, hypochromic anemia may be observed. Signs of hepatic damage have also been described, and can vary in severity from elevated serum transaminase activity to life-threatening liver fail-transplantation, the number of fluorescent erythrocytes decreased from 61% (EPP mice) to 19% for EPP mice engrafted with low fluorescent selected BM cells. Absence of skin photosensitivity was observed in mice with less than 20% of fluorescent RBC. A partial phenotypic correction was found for animals with 20 to 40% of fluorescent RBC. In conclusion, a partial correction of bone marrow cells is sufficient to reverse the porphyric phenotype and restore normal hematopoiesis. This selection system represents a rapid and efficient procedure and an excellent alternative to the use of potentially harmful gene markers in retroviral vectors. Gene Therapy (2001) 8, 618-626.
ure, which necessitates liver transplantation. 1, 2, [4] [5] [6] [7] The therapy of EPP is often limited to supportive care and is only partially successful, especially in the severe forms. This monogenic disorder starts early in infancy and represents a good candidate for gene therapy in severe forms since the genetic defect is well characterized at the molecular level. Generally, EPP is an autosomal dominant disease, but in some cases it is transmitted in a recessive fashion. [8] [9] [10] Following the cloning of the human ferrochelatase cDNA, several mutations have been identified showing a high molecular heterogeneity. [8] [9] [10] [11] [12] [13] The pathophysiology of the human disease is still unclear, particularly with respect to the development of liver failure.
14 Acute hepatic failure is due to the accumulation of protoporphyrin in the liver. Because the protoporphyrin mostly originates from the erythroid cells, bone marrow (BM) transplantation can be a convenient therapy for severe cases of EPP. An EPP patient who underwent allogeneic BM transplantation for leukemia had complete hematologic remission. 15 A murine model of EPP, the Fech m1Pas /Fech m1Pas mouse 16, 17 was used for cell 18, 19 and gene therapy. 18 The replacement of the major part of the deficient BM cells by normal ones was able to reduce protoporphyrin accumulation in erythrocytes. Also, gene therapy to the bone marrow in the same model can reverse the protoporphyrin accumulation as well as the photosensitization associated with the porphyria. 18 Interestingly, BM transplantation performed in very young animals (3-4 weeks old) can prevent hepatobiliary complications as well as hepatocyte alterations and partially revert protoporphyrin accumulation in the liver. 19 However, allogeneic BM transplantation is limited by the need for an HLA-matched donor. In the absence of a suitable donor, autografting of genetically modified hematological cells seems to be an appealing alternative. An important step in view of future gene therapy in humans is developing efficient selection procedures to increase the frequency of genetically corrected cells before autologous transplantation. One approach relies on the expression of a cotransfected marker gene. In the recent work of Pawliuk et al, 18 a high proportion of transduced BM cells carrying the human ferrochelatase cDNA were selected ex vivo on the basis of the co-expression of the green fluorescent protein (EGFP). The authors demonstrated a complete and long-term correction of photosensitivity in this murine EPP model. However, the approach using vectors encoding gene markers is not acceptable for use in humans. The aim of our study was to develop a method of preselecting genetically corrected cells before transfusion using a method based on the expression of the therapeutic gene, rather than on the expression of a potentially toxic marker gene.
Results
In vitro transduction of interleukin-3-dependent hematopoietic precursor cell line FDCP1 The Gp+env86/LFSN17 clone was selected for subsequent experiments because of its high retroviral production (1.3 × 10 6 c.f.u.). Supernatants from this clone and the control Gp+env86/LXSN clone were used to transduce the FDCP1 cells in Retronectin-coated wells. Two days after the infection, cells were selected in the presence of 1 mg/ml G418 for 2 weeks. A Southern blot analysis showed that transduced and selected FDCP1 cells carried two to three copies of the vector per cell (Figure 1a ). Ferrochelatase activity was 5.4-fold higher in these cells compared with the LXSN-transduced or nontransduced FDCP1 cells (Figure 1b ). This clone was therefore selected for the transduction of BM cells from EPP mice.
Transduction of BM cells, fluorescence-based selection and reimplantation into mice Two transduction experiments were performed. The first experiment showed that 25% of colony-forming cells (CFC) were resistant to G418; 3.5 × 10 5 of these cells were injected directly into two different EPP mice. The second experiment gave rise to a 33% transduction in CFC. Again observed after 24 h of ALA addition (data not shown). Flow cytometry analysis of normal and deficient BM cells is shown in Figure 2a Hematological, enzymatic and metabolic correction of the engrafted mice Hematological parameters (Table 1 ) observed in mice grafted with transduced and nonselected BM cells (group 3) were close to those of EPP mice (group 2). By contrast, red blood cell (RBC) count, hematocrit and hemoglobin concentration were normalized in mice grafted with transduced and low fluorescent-selected BM cells (group 4).
Bone marrow cells from animals grafted with transduced and nonselected BM cells (group 3) showed a low ferrochelatase activity (Table 2) , not significantly different from the porphyric mice (group 2). However, cells from animals grafted with low-fluorescent BM cells showed the same ferrochelatase activity as the normal mice (group 1). BM protoporphyrin levels in EPP mice grafted (Table  2) , with nonselected or low-fluorescent selected BM cells were reduced 1.9-and 9.2-fold, respectively, compared with EPP mice, demonstrating the efficiency of the selection of genetically corrected cells. These results were confirmed by the study of the percentage of fluorescent RBC cells shown in Figure 3 . This percentage was slightly reduced in mice grafted with nonselected BM cells (group 3: 47% versus 61% for group 2, EPP mice) but was highly reduced in mice grafted with low fluorescent-selected BM cells (group 4: 19% versus 61% in group 2, P Ͻ 0.01). However, correction was not total when compared with control animals (group 1: 4.7%, P Ͻ 0.01).
Skin photosensitivity
To study the cutaneous photosensitivity of the different groups of mice, a dose of 8 J/cm 2 was chosen because we observed some apoptotic cells in wild-type mice with the higher dose of 10 J/cm 2 (data not shown). Damage in skin and the ear extremities began to appear 24 h following light exposure in EPP mice. Five days after irradiation, skin damage in deficient mice was accentuated ( Figure 4a ), whereas we did not observe any lesions on wild-type mice (Figure 4d ). Histological sections confirmed these observations with a high percentage of dead cells in the epidermis and dermis, and an extensive inflammatory infiltrate (Figure 4g ). Wild-type mice showed no damage microscopically (Figure 4h ). Mice grafted with nonselected cells presented either a skin response similar to the EPP mice (the two mice engrafted with 25% of transduced cells at the time of Figure 4b ). Three out of four mice grafted with low fluorescent-selected BM cells and exposed to light did not present any macroscopic damage (Figure 4c ), as observed in wild-type mice. Microscopically, one mouse presented with only a small localized inflammatory infiltrate in the hypodermis (Figure 4f ).
Liver damage EPP mice showed a marked hepatomegaly when compared with the control group (10.1% of liver weight per total body weight versus 4.8%, respectively; see Table 1 ). 
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No changes in organ weight were observed in mice grafted with nonselected or high-fluorescent selected cells. By contrast, hepatomegaly was less severe in mice grafted with low-fluorescent selected BM cells (7.1% versus 10.1% in EPP mice, P Ͻ 0.01). Normal mice showed typical liver histology with sinusoids carrying blood in the parenchymal tissue. Liver from deficient mice presented large discrete areas delimited by a dense collagen network, widely called regenerative nodules.
Serum from mice grafted either with nonselected or low-fluorescent selected transduced BM cells showed reduced alkaline phosphatase levels ( Table 1) . As expected, liver ferrochelatase activity was not modified after BM transplantation (Table 2 ). However, the hepatic protoporphyrin level was reduced in deficient mice grafted with low-fluorescent selected BM cells (Table 2 , group 4).
Provirus integration in CFC from bone marrow of grafted mice
Five months after transplantation, an obvious increase of transduced CFC was observed in mice grafted with lowfluorescent selected BM cells (44%, range 25-52%) when compared with animals injected with transduced and nonselected BM cells (2.5%, range 0-8%) ( Figure 5 ).
Figure 5 Identification of LFSN proviruses by in vitro amplification (PCR). A total of 25 CFC from BM of each grafted mice was analyzed for the presence of the provirus by nested PCR using specific primers designed from a sequence located in the LFSN vector: Fech A: 5Ј-CCT ATT CAG AAT AAG CTG GC-3Ј, Fech B: 5Ј-CAG AAT AAG CTG GCA CCA TTC-3Ј, Fech C: 5Ј-CTG CCT GTG GTG GAG CAG-3Ј, Fech D: 5Ј-AAG CTG CTG CCT GTG GTG-3Ј. The final PCR amplified a 270 bp product from human ferrochelatase cDNA.

Discussion
Human EPP is a monogenic disorder characterized clinically by cutaneous photosensitivity, sometimes mild anemia, and biochemically by the accumulation of excessive amounts of photoreactive protoporphyrin. ␤-Carotene is effective in preventing skin photosensitivity in some cases of EPP. 20 Allogeneic BM transplantation might be an option to cure this disease. In the unique report of a bone marrow transplantation in an EPP patient, 15 a complete remission of the porphyric phenotype was observed 5 months after transplantation. As in this patient, transplantation of normal BM cells into the Fech m1pas /Fech m1pas mutant mouse was efficient in decreasing protoporphyrin accumulation in the blood. It can also prevent hepatobiliary complications and reverse hepatic protoporphyrin accumulation. 19 BM cells and specifically hematopoietic stem cells (HSC) are considered as good targets for retrovirus-mediated gene therapy of immunological 21, 22 and hematological 23 genetic diseases like EPP. One approach for gene therapy is to introduce ex vivo a normal counterpart of the defective gene into the HSC of the affected patient, and to return it as an autologous BM transplant. To facilitate future ex vivo gene therapy in humans, a critical point is the design of efficient selection procedures aimed at increasing the frequency of genetically corrected cells before autologous transplantation. The selection approach uses vectors encoding marker genes, such as GFP, 18, 24 or genes conferring cellular resistance to potentially toxic drugs such as neomycin, hygromycin, puromycin and dihydrofolate reductase (DHFR) or multi-drug resistance (MDR-1) systems. 23 A long-term cure of the photosensitivity in the Fech m1pas /Fech m1pas mouse model was obtained by a preselective gene therapy protocol using GFP. 18 In the current study, we wanted to use an approach applicable in humans. Previous work performed on lymphoblastoid cells from two other erythropoietic porphyrias, ie congenital erythropoietic porphyria and hepato-erythropoietic porphyria, demonstrated the feasibility of a fluorescence-based selection of genetically corrected cells. 25, 26 We applied this system to the BM cells of the EPP mouse model. Because of the specific fluorescence of porphyrins, the development of an efficient strategy of selecting transduced cells depends on a clear difference in porphyrin accumulation between deficient and corrected cells. The presence of exogeneous ALA, a heme precursor, induces an increase in porphyrin fluorescence in deficient cells detected by cytofluorimetry. This selection procedure eliminates the use of a marker gene for determining that the BM cells have received the therapeutic gene. However, the LXSN vector contains the Neo gene, the product of which is an antigenic protein. For human use, a retroviral vector without such a selection gene will have to be considered in view of gene therapy in humans.
Animals grafted with transduced and low-fluorescent selected BM cells showed a restoration of BM ferrochelatase activity, in contrast to the low activity remaining in the nonselected transduced BM cells. In the same manner, the porphyrin level was normalized in BM of animals grafted with low-fluorescent selected BM cells. These results demonstrate the efficacy of the fluorescence-based selection system. Long-term correction (5 months) demonstrated that short-and long-term reconstituting cells were efficiently transduced and selected.
Since 44% of CFC carried the provirus and because of a global 120% enzymatic activity in the BM cells, it can be concluded that expression of the transgene was at least two-fold that of the endogenous gene. Strict gene regulation is not required for EPP, because ferrochelatase is not the key-limiting enzyme of the heme synthesis pathway. Because the porphyric phenotype seemed to be a consequence of the accumulation of protoporphyrin in different tissues, we analyzed this parameter in BM, RBC and liver. Only about 60% of the RBC in the EPP mice had high protoporphyrin levels. In the erythroid lineage, protoporphyrin accumulation was highest in erythroblasts and reticulocytes compared with RBC. During the life time of RBC, protoporphyrin can cross the membrane due to its lipophilic characteristics, 27 leading to a decreased porphyrin concentration with age. 28 RBC count was normalized in mice grafted with low-fluorescent transduced BM cells. This means that the erythroid cells of these animals had a longer life due to less direct porphyrin toxicity and less destruction of maturing corrected RBC. In this way, Koningsberger et al 29 provided evidence that protoporphyrin can induce the generation of oxygen-free radicals, in particular hydrogen peroxide, which can yield OH radicals in iron/copper-driven Fenton chemistry. The latter compounds are a very potent oxidant; they are able to initiate a chain reaction of lipid peroxidation, to disturb the structure and function of cellular membranes and to reduce the life RBC. The hemoglobin level was also normalized in animals grafted with selected BM cells. Because the activity of ferrochelatase is rate-limiting for heme synthesis in EPP, 30 restored activity of this enzyme in BM is consistent with an increase in heme and hemoglobin in the RBC.
In our experiments, even a partial correction of the BM cells led to a therapeutic effect on the EPP mice. Absence of skin photosensitivity was observed in mice with less than 20% of fluorescent RBC. Moreover, a partial phenotypic correction was found for animals with 20 to 40% of fluorescent RBC.
Restoration of hepatic function depended on the percentage of genetically corrected cells in the graft. Biliary excretion was also improved, as indicated by reduction of the alkaline phosphatase level. Reduction of protoporphyrin production from the BM and increased biliary excretion resulted in a decrease in protoporphyrin levels in the liver.
In conclusion, fluorescence-based selection of corrected cells is an efficient procedure leading to long-term expression of the transgene from progenitors to differentiated hematopoietic cells. In this model, a partial correction of bone marrow cells was sufficient to reduce the production of protoporphyrin and its accumulation in RBC and liver, with an improvement in skin photosensitivity and anemia in EPP mice. The features of this porphyric mouse mimic those of human erythropoietic protoporphyria. These data provide support for the feasibility of gene therapy in EPP patients with severe photosensitivity that does not respond to presently available methods of photoprotection, and in patients with extremely high levels of protoporphyrin that put them at risk of developing potentially lethal protoporphyrininduced liver damage.
Gene Therapy
Materials and methods
Retroviral construct and packaging cell lines A normal full-length human ferrochelatase cDNA (1.6 kb) was cloned into the unique EcoRI-BamHI sites of the pLXSN vector 31 to obtain pLFSN. The gene of interest is driven by the MoMLV/MoMSV LTR. The vector contains the Neo R gene which allowed the selection of transduced cells by G418 (Geneticin; Gibco BRL, Grand Island, NY, USA). The LFSN construct was transfected into the amphotropic packaging cell line -CRIP by DOTAP transfection reagent (Boehringer Mannheim, Meylan, France). Transfectants were selected in the presence of 1 mg/ml G418 for 2 weeks. Filtered supernatants from virus-producing cells were used to infect ecotropic Gp+env86 cells in the presence of 8 g/ml protamine sulfate (Sigma, St Louis, MO, USA). Two days after transduction, cells were selected in the presence of 1 mg/ml G418 for 2 weeks. Twenty-three resistant clones were isolated. Viral titers were measured using NIH3T3 cells as a target. Supernatants were tested for the presence of replication-competent virus. 32 The clones producing the highest viral titer were analyzed for ferrochelatase expression using the FDCP1 cells.
Packaging and NIH3T3 cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% heat-inactivated fetal calf serum (FCS; BioWhittaker, Emerainville, France), 100 units/ml penicillin and 0.1 mg/ml streptomycin at 37°C in 5% CO 2 atmosphere. FDCP1 cells were maintained by standard procedures in ␣-MEM medium, supplemented with 10% heat-inactivated FCS, 10% of supernatant of WEHI cells, 100 units/ml penicillin and 0.1 mg/ml streptomycin at 37°C in 5% CO 2 atmosphere. FDCP1 cells were transduced by retroviral supernatant from the Gp+env86/LFSN17 and the Gp+env86/LXSN clones at a multiplicity of infection (MOI) of 20 for 24 h.
Preparation and transduction of BM cells from normal and deficient mice
The Fech m1pas /Fech m1pas mutant mice (BALB/cJ) were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). A colony was established in the animal facility of the Université Victor Segalen Bordeaux 2. All mice were kept under pathogen-free conditions in air-filtered cages and were provided with autoclaved food and water. The mice were maintained with unlimited water and standard laboratory chow under 12 h light/dark cycles. Homozygous males (Fech m1pas /Fech m1pas ) were crossed with heterozygous females (Fech m1pas /+) and homozygous pups were characterized by their high RBC porphyrin concentration. All the animal experimentations were conducted in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals.
Donor male mice (8 to 12 weeks old) were intraperitoneally injected with 5-fluorouracil (150 mg/kg per mouse). Five days after injection the donor mice were killed, then BM cells were collected by flushing the marrow from the two femurs and tibias. Cells were dispersed using a 21-gauge needle and RBC were eliminated by hypotonic lysis. Remaining BM cells were washed twice with phosphate-buffered saline (PBS) and were incubated in ␣-MEM medium, supplemented with 12% fetal calf serum (FCS), 12% horse serum, 10% supernatant of WEHI cells, 5% supernatant of COS cells transfected with recombinant murine stem cell factor (rmSCF; Genetic Institute, Cambridge, MA, USA), 100 units/ml penicillin and 0.1 mg/ml streptomycin at 37°C in 5% CO 2 atmosphere.
For the transduction procedure, isolated nucleated BM cells were resuspended at a concentration of 5 × 10 5 cells/ml in virus supernatant supplemented with 12% horse serum, 10% of supernatant of WEHI cells and 5% of supernatant of COS cells transfected with rmSCF. Cells were seeded in RetroNectin (Takara, Boehringer Ingelheim, Germany)-coated wells and incubated at 37°C under 5% CO 2 atmosphere for 12 h. Then, the supernatant was replaced by fresh medium and incubated for 36 h. Two days after infection, 2.5 × 10 4 nucleated BM cells were seeded in a methylcellulose-based medium (HCC-4230; StemCell Technologies, Tebu, Meylan, France) with 10% horse serum, 8% supernatant of WEHI cells, 4% supernatant of genetically modified COS cells. Cultures were performed in the presence and absence of G418 to underline CFC at day 12.
Fluorescence-based selection of retrovirally transduced cells and BM transplantation Forty-eight hours after the infection of deficient BM cells, medium was replaced by ␣-MEM medium containing 7% FCS, 1 mmol/l ALA, 2 mmol/l melatonin 25 (protecting agent) and 50 mol/l FeSO 4 (Sigma, Saint-Quentin, France) at pH 7.4. Cell sorting experiments were performed 24 h after addition of ALA. Cells were harvested and concentrated at 10 6 cells/ml and sorted by flow cytometry at a rate of 1500 events/s using an Elite Cytometer (Coulter, Margency, France). An excitation light source between 340 nm and 360 nm was used and fluorescence was measured through a 675 nm band filter. Sorted cells were collected in 5 ml sterile tubes containing 0.5 ml FCS.
Recipient female mice (21-28 days old) were lethally irradiated with two doses of 6 Gy (␥-rays) spaced 24 h apart 33 to suppress the endogenous hematopoiesis. Each recipient received 3.5 × 10 5 nucleated BM cells from donor male mice 4 h after the second dose of irradiation. 
Analysis of chimerism in transplanted mice
The use of males as donors and females as recipients made it possible to determine chimerism by fluorescence in situ hybridization (FISH). Bone marrow cells were hybridized with a Y FITC labeled-paint probe for the mouse chromosome Y and a Cyanin 3 labeled-paint probe for the mouse chromosome X (Valbiotech, Paris, France), as described previously. 19 A minimum of 200 cells was examined.
Hematological and biochemical measurements Recipient mice were killed 6 days after UVA exposition for biochemical, molecular and histological analysis. The animals were weighed, then anesthetized with a pentobarbital injection and killed by exsanguination. Blood samples were collected through cardiac puncture for hematological and biochemical parameters. Skin, liver, spleen and BM cells were immediately removed. Liver was weighed before processing samples. Single-cell suspensions were obtained by passing marrow cells through a 21-gauge needle. Red cells were eliminated by hypotonic lysis and nucleated BM cell number was estimated in a Malassez count slide. Hemoglobin, hematocrit, cell count and volume parameters were measured in a Coulter Counter (Coultronics, Margency, France). Serum, alanine transaminase and alkaline phosphatase were determined by standard methods in a CX7 (Beckman, France). Ferrochelatase activity was measured in the BM and liver according to Camadro and Labbe. 34 Protoporphyrin levels in RBC, plasma and organs were determined spectrofluorimetrically 35 using a Hitachi F-4500 fluorescence spectrophotometer (Braun Sciencetec, Les Ulis, France) (excitation 405 nm and emission 605 nm), after extraction with 1 mol/l HCLO 4 /CH 3 OH (1:1, v/v). Percentage of fluorescent RBC was scored at the end of the study. Blood from transplanted mice was diluted in PBS and analyzed by flow cytometry (Coulter Elite) using a 340-360 nm UV light excitation and channel FL3 (Ͼ650 nm) to characterize porphyrin fluorescence.
Detection of provirus integration by polymerase chain reaction (PCR)
Fifty thousand BM cells from grafted mice were harvested and plated in a methylcellulose-based medium as described above. CFC were scored on day 12 and a minimum of 25 colonies from each mouse was picked, rinsed twice with PBS and frozen. Cells were then digested with proteinase K in lysis buffer (10 mmol/l Tris-Cl, pH 8.0, 50 mmol/l KCl, 2.5 mmol/l MgCl 2 , 0.5% Tween-20, 100 g/ml proteinase K) at 55°C for 2 h, followed by a 10 min exposure at 95°C to inactivate the proteinase K. The presence of the provirus was characterized by nested PCR using specific primers designed from a sequence located in the LFSN vector: Fech A: 5Ј-CCT ATT CAG AAT AAG CTG GC-3Ј, Fech B: 5Ј-CAG AAT AAG CTG GCA CCA TTC-3Ј, Fech C: 5Ј-CTG CCT GTG GTG GAG CAG-3Ј, Fech D: 5Ј-AAG CTG CTG CCT GTG GTG-3Ј. The final PCR amplified a 270 bp product from human ferrochelatase cDNA. Each reaction was analyzed by agarose gel electrophoresis and the specific PCR fragment was detected under a UV light after ethidium bromide staining.
Skin photosensitivity and morphological studies Reversal of skin photosensitivity was assayed 20 weeks after transplantation using an irradiation protocol. Dorsal mouse skin was depilated in order to render mouse skin accessible to irradiation. Twenty-four hours later, mice were irradiated 30 cm from the light source. A dose of 8 J/cm 2 UVA was delivered with a Biotronic device (Vilber Lourmat, Marne La Vallée, France). The UVA lamp delivered UV in the range 312-400 nm with a peak at 365 nm. Skin pictures were taken 5 days after irradiation.
Sheets of dorsal mouse skin were fixed in 4% formalin, dehydrated, embedded in paraffin, cut in 5 m sections and stained with hematoxylin-eosin to visualize the irradiation-induced damage.
Liver histology
The liver was removed, weighed, rinsed in ice-cold PBS, divided and fixed in 4% paraformaldehyde by immersion for 48 h. Pieces were then embedded in paraplast, cut in 5 m slices and the sections were collected on gelatincoated slides and stained with Masson trichrome. 36 The sections were then dehydrated, mounted in Eukitt and observed under a Leica LR microscope. Cell surface was estimated from randomly chosen sections in each group. Only cells that had a distinguishable nucleus were analyzed. A total of 1000 cells in each group was measured. Measurements were performed on an image analysis system (Histo200; Biocom, Les Ulis, France).
Statistical analysis
The results are expressed as median and range. One-way analysis of variance (ANOVA) was used for comparison of differences between groups of transplanted mice. When the group variances were unequal as tested by Cochran's test, the data were transformed logarithmically [log (1 + X)] before analysis. The null hypothesis was rejected when P Ͻ 0.05.
